Thomas Krenitsky, CEO Krenitsky Pharmaceuticals, Former VP Research 1989-1995

Dr Krenitsky joined BW in 1966 as a biochemist, working with Elion and Hitchings. In 1989 he became Vice-President of Research and left the company in 1995.

Topics discussed include:

*Bill Creasy, his working relationship with staff, management style, and departure from the company

* Empirin

* Gertrude Elion and George Hitchings, their approach to research and staff, obtaining internal and external funding, standing within the scientific community, Noble Prize

* Sloan Kettering Institue

*Howard Schaeffer

* Fred Coe, management style

* BW working atmosphere

* marketing within BW

* Wellbutrin

* Zovirax

* differences between BW in UK and USA, why UK was less successful than USA

* John Vane and Moncada

* lamontrigine and trimethoprim

* Pedro Cuatrecasas, inc management style

* Bill Sullivan, management style, relationship with Hitchings

* Peter Howsam

* flotation

* Ted Haigler

* Lil Beauchamp

* acyclovir, inc pricing

* AZT, Retrovir and pricing

* merger with Glaxo

* Glaxo's marketing function

* comments on the company post merger.

1 audiocassette Tape 24

Copyright was assigned to the Wellcome Trust for all material created or commissioned by the Wellcome Foundation, its successors and associated companies. The copyright in third party material (ie material not created by WF such as letters and publications from external sources, magazine articles, newspaper cuttings etc) is assumed to remain with the creator or his/her heirs. Where third party material exists, this has been noted at item level.

This item needs to be accessed onsite using specialist equipment. Email collections@wellcomecollection.org to request an appointment.